Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNONCOVID: GNS561, Monalizumab, and Avdoralimab in Cancer Patients with COVID-19
NCT04333914Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Apr 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ezurpimtrostat, monalizumab, avdoralimab in coronavirus disease 2019 (COVID-19), sponsored by Centre Léon Bérard. Started Apr 2020; status: completed.
02
Drugs
ezurpimtrostatmonalizumabavdoralimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04333914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333914.